Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO

NCT ID: NCT03203447

Last Updated: 2021-04-23

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

325 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-03-05

Study Completion Date

2018-12-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This Phase 3, multicenter, randomized, masked, controlled, parallel group study is designed to demonstrate that suprachoroidal (SC) CLS-TA administered with intravitreal (IVT) anti-VEGF agent in subjects with treatment naive RVO is superior to IVT anti-VEGF agent used alone.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A Randomized, Masked, Controlled Trial to Study the Safety and Efficacy of Suprachoroidal CLS-TA With Intravitreal Anti-VEGF Agent in Subjects With Retinal Vein Occlusion

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Macular Edema Retinal Vein Occlusion

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active

Lucentis (0.5 mg/0.05 mL), IVT injection + CLS-TA (4 mg/0.10 mL), SC injection or Avastin (1.25 mg/0.05 mL), IVT injection + CLS-TA (4 mg/0.10 mL), SC injection

Group Type ACTIVE_COMPARATOR

suprachoroidal CLS-TA

Intervention Type DRUG

suprachoroidal injection of CLS-TA

Lucentis or Avastin

Intervention Type DRUG

IVT anti-VEGF agent. Either a 0.5 mg intravitreal injection of Lucentis or 1.25 mg intravitreal injection of Avastin

Control

Lucentis (0.5 mg/0.05 mL), IVT injection + sham SC procedure or Avastin (1.25 mg/0.05 mL), IVT injection + sham SC procedure

Group Type SHAM_COMPARATOR

suprachoroidal sham

Intervention Type DRUG

sham suprachoroidal procedure

Lucentis or Avastin

Intervention Type DRUG

IVT anti-VEGF agent. Either a 0.5 mg intravitreal injection of Lucentis or 1.25 mg intravitreal injection of Avastin

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

suprachoroidal CLS-TA

suprachoroidal injection of CLS-TA

Intervention Type DRUG

suprachoroidal sham

sham suprachoroidal procedure

Intervention Type DRUG

Lucentis or Avastin

IVT anti-VEGF agent. Either a 0.5 mg intravitreal injection of Lucentis or 1.25 mg intravitreal injection of Avastin

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Triamcinolone acetonide IVT anti-VEGF agent

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Has a clinical diagnosis of RVO in the study eye
* Has a CST of ≥ 300 µm in the study eye
* Has an ETDRS BCVA score of ≥ 20 letters read and ≤ 70 letters read in the study eye
* Is naïve to local pharmacologic treatment for RVO in the study eye

Exclusion Criteria

* Any active ocular disease or infection in the study eye other than RVO
* History of glaucoma, intraocular pressure \> 21 mmHg or ocular hypertension requiring more than one medication
* Any uncontrolled systemic disease that, in the opinion of the Investigator, would preclude participation in the study
* Any evidence of neovascularization in the study eye
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Clearside Biomedical, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Thomas Ciulla, MD

Role: STUDY_DIRECTOR

Chief Medical Officer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Retinal Research Institute

Phoenix, Arizona, United States

Site Status

Retina Centers PC

Tucson, Arizona, United States

Site Status

Retina Associates Southwest PC

Tucson, Arizona, United States

Site Status

Win Retina

Arcadia, California, United States

Site Status

Retina Vitreous Medical Group

Beverly Hills, California, United States

Site Status

Retinal Diagnostic Center

Campbell, California, United States

Site Status

Retina Consultants of Orange County

Fullerton, California, United States

Site Status

Macula and Retina Institute

Glendale, California, United States

Site Status

American Institute of Research

Los Angeles, California, United States

Site Status

Retina Vitreous Associates Medical Group Inc

Mountain View, California, United States

Site Status

Stanford University - Byers Eye Institute

Palo Alto, California, United States

Site Status

Retina Consultants of Southern California

Redlands, California, United States

Site Status

Retina Consultants Medical Group Inc

Sacramento, California, United States

Site Status

American Institute of Research

Whittier, California, United States

Site Status

Retina Group of New England, PC

New London, Connecticut, United States

Site Status

Florida Eye Microsurgical Institute

Boynton Beach, Florida, United States

Site Status

Specialty Retina Center

Coral Springs, Florida, United States

Site Status

National Ophthalmic Research Institute

Fort Myers, Florida, United States

Site Status

Center for Retina Care at The Eye Institute

Melbourne, Florida, United States

Site Status

Florida Retina Institute

Orlando, Florida, United States

Site Status

Eye Associates of Pinellas

Pinellas Park, Florida, United States

Site Status

Retina Vitreous Associates of Florida

St. Petersburg, Florida, United States

Site Status

East Florida Eye Institute EFEI

Stuart, Florida, United States

Site Status

Southern Vitreoretinal Association

Tallahassee, Florida, United States

Site Status

Center for Retina And Macular Disease

Winter Haven, Florida, United States

Site Status

Retina Consultants of Hawaii

‘Aiea, Hawaii, United States

Site Status

Gailey Eye Clinic

Bloomington, Illinois, United States

Site Status

University and Macula Associates

Oak Forest, Illinois, United States

Site Status

Prairie Eye Center, Ltd.

Springfield, Illinois, United States

Site Status

Sabates Eye Centers

Leawood, Kansas, United States

Site Status

Vitreo-Retinal Consultants and Surgeons PA

Wichita, Kansas, United States

Site Status

Central Plains Eye MDs

Wichita, Kansas, United States

Site Status

Paducah Retinal Center

Paducah, Kentucky, United States

Site Status

Retina Specialists

Baltimore, Maryland, United States

Site Status

The Retina Care Center

Baltimore, Maryland, United States

Site Status

Retina Group of Washington

Chevy Chase, Maryland, United States

Site Status

Cumberland Valley Retina Consultants

Hagerstown, Maryland, United States

Site Status

The National Retina Institute

Towson, Maryland, United States

Site Status

Ophthalmic Consultants of Boston

Boston, Massachusetts, United States

Site Status

New England Retina Consultants

Springfield, Massachusetts, United States

Site Status

Associated Retinal Consultants PC

Grand Rapids, Michigan, United States

Site Status

Vitreo-Retinal Associates, P.C.

Grand Rapids, Michigan, United States

Site Status

Associated Retinal Consultants P.C.

Royal Oak, Michigan, United States

Site Status

Retina Consultants of Michigan

Southfield, Michigan, United States

Site Status

Associated Retinal Consultants PC

Traverse City, Michigan, United States

Site Status

Retina Associates of St. Louis

Florissant, Missouri, United States

Site Status

Retina Consultants of Nevada

Las Vegas, Nevada, United States

Site Status

Sierra Eye Associates

Reno, Nevada, United States

Site Status

Ophthalmic Consultants of Long Island

Lynbrook, New York, United States

Site Status

Retina Associates of Western New York

Rochester, New York, United States

Site Status

Island Retina

Shirley, New York, United States

Site Status

Retina-Vitreous Surgeons of Central New York

Syracuse, New York, United States

Site Status

Retina Associates of Cleveland Inc

Middleburg Heights, Ohio, United States

Site Status

Dean A. McGee Eye Institute

Oklahoma City, Oklahoma, United States

Site Status

Pennsylvania Retina Specialists PC

Camp Hill, Pennsylvania, United States

Site Status

Black Hills Regional Eye Institute

Rapid City, South Dakota, United States

Site Status

Texas Retina Associates - Arlington

Arlington, Texas, United States

Site Status

Austin Retina Associates

Austin, Texas, United States

Site Status

Retina Research Center

Austin, Texas, United States

Site Status

Texas Retina Associates

Dallas, Texas, United States

Site Status

Retina and Vitreous of Texas, PLLC

Houston, Texas, United States

Site Status

Retina Consultants of Houston, PA

Houston, Texas, United States

Site Status

Valley Retina Institute, PA

McAllen, Texas, United States

Site Status

Retina Specialists

Plano, Texas, United States

Site Status

San Antonio Eye Center

San Antonio, Texas, United States

Site Status

Medical Center Ophthalmology Associates

San Antonio, Texas, United States

Site Status

Retina Associates of South Texas PA

San Antonio, Texas, United States

Site Status

Retina Consultants of Houston, PA

The Woodlands, Texas, United States

Site Status

Strategic Clinical Research Group, LLC

Willow Park, Texas, United States

Site Status

Rocky Mountain Retina Consultants

Salt Lake City, Utah, United States

Site Status

Retina Group of Washington

Fairfax, Virginia, United States

Site Status

West Virginia University Medicine Eye Institute

Morgantown, West Virginia, United States

Site Status

Eye Clinic Albury Wodonga

Albury, New South Wales, Australia

Site Status

Strathfield Retina Clinic

Strathfield, New South Wales, Australia

Site Status

Save Sight Institute, University of Sydney (Sydney Eye Hospital)

Sydney, New South Wales, Australia

Site Status

MH EK Honvédkórház

Budapest, , Hungary

Site Status

Raghudeep Eye Hospital

Gujrāt, Ahmedabad, India

Site Status

LV Prasad Eye Institute

Hyderabad, Andhra Pradesh, India

Site Status

L V Prasad Eye Institute

Visakhapatnam, Andhra Pradesh, India

Site Status

R.P. Centre, AIIMS

New Delhi, Ansari Nagar, India

Site Status

Narayana Nethralaya

RajajiNagar, Bangalaore, India

Site Status

LV Prasad Eye Institute

Patia, Bhubaneswar, India

Site Status

M&J Western Regional Institute of Ophthalmology

Asarwa, Gujarat, India

Site Status

PBMA's H.V Desai Eye Hospital

Pune, Maharashtra, India

Site Status

Dr Shroff 's Charity Eye Hospital

Delhi, New Delhi, India

Site Status

Regional Institute of Ophthalmology

Bīhar, Patna, India

Site Status

B B Eye Foundation VIP

Kolkata, Raghunathpur, India

Site Status

SMS Hospital

Jaipur, Rajasthan, India

Site Status

Aravind Eye Hospital

Madurai, Tamil Nadu, India

Site Status

Jawaharlal Rohatgi Eye Hospital

Kanpur, Uttar Pradesh, India

Site Status

Disha Eye Hospitals Pvt. Ltd.

Kolkata, West Bengal, India

Site Status

Auckland Eye

Auckland, , New Zealand

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Hungary India New Zealand

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CLS1003-302

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Phase II/III Study of Anti-VEGF in Neovascular AMD
NCT00021736 COMPLETED PHASE2/PHASE3